New drug aramchol aims to reverse fatty liver damage in phase 3 trial

NCT ID NCT04104321

Terminated Disease control Sponsor: Galmed Research and Development, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see if the drug can reduce liver scarring and improve liver health. The study was paused due to COVID-19 and results are expected in 2027.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS (NASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver diabetes mellitus Fibrosis metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONALCOHOLIC STEATOHEPATITIS (NASH)

Contacts and locations

Show contact details

Locations

Texas Clinical Research Institute, LLC

Arlington, Texas, 76012, United States
The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System

Miami, Florida, 33136, United States